Homology modeling and substrate binding study of human CYP2C9 enzyme
暂无分享,去创建一个
[1] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[2] H. Yamazaki,et al. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. , 1997, Archives of biochemistry and biophysics.
[3] A. Fulco,et al. Involvement of a single hydroxylase species in the hydroxylation of palmitate at the ω—1, ω—2 and ω—3 positions by a preparation from Bacillus megaterium , 1976 .
[4] T. Poulos,et al. The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.
[5] P. Ortiz de Montellano,et al. Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. , 1994, The American journal of physiology.
[6] D. Lewis. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[7] J Deisenhofer,et al. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.
[8] G. Loew,et al. Homology Modeling of Horseradish Peroxidase , 1995 .
[9] T. Kronbach,et al. A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1. , 1991, Biochemistry.
[10] A. Fulco,et al. Epoxidation of unsaturated fatty acids by a soluble cytochrome P-450-dependent system from Bacillus megaterium. , 1981, The Journal of biological chemistry.
[11] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[12] T. Richardson,et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. , 1995, Archives of biochemistry and biophysics.
[13] T. Richardson,et al. Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P450 2C3v. , 1994, The Journal of biological chemistry.
[14] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[15] J. Goldstein,et al. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.
[16] P. Beaune,et al. Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. , 1996, Pharmacogenetics.
[17] B. Monsarrat,et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. , 1997, Bulletin du cancer.
[18] D. Mansuy,et al. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.
[19] B. Kemper,et al. Differential effects of mutations in substrate recognition site 1 of cytochrome P450 2C2 on lauric acid and progesterone hydroxylation. , 1994, Biochemistry.
[20] J. Halpert,et al. Epoxidation of arachidonic acid as an active-site probe of cytochrome P-450 2B isoforms. , 1994, Biochimica et biophysica acta.
[21] Pei-Fung Wu,et al. cDNA sequence analysis and mutagenesis studies on the a chain of Β-bungarotoxin from Taiwan banded krait , 1996, Journal of protein chemistry.
[22] L. Li,et al. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. , 1998, Archives of biochemistry and biophysics.
[23] O. Stiffelman,et al. Computer modeling of 3D structures of cytochrome P450s. , 1996, Biochimie.
[24] K Chiba,et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.
[25] J. Miners,et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.
[26] P. Lu,et al. Heme-coordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation. , 1997, Archives of biochemistry and biophysics.
[27] O. Pelkonen,et al. Role of Environmental Factors in the Pharmacokinetics of Drugs: Considerations with Respect to Animal Models, P-450 Enzymes, and Probe Drugs , 1994 .
[28] S. Kitareewan,et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.
[29] E. Sellers,et al. Drug Kinetics and Alcohol Ingestion , 1978, Clinical pharmacokinetics.
[30] J. Goldstein,et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.
[31] D A Smith,et al. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.
[32] J. Peterson,et al. Mechanism‐based probes of the topology and function of fatty acid hydroxylases , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] K. Suslick,et al. Shape selective alkane hydroxylation by metalloporphyrin catalysts , 1987 .
[34] G. Loew,et al. Prediction of Regiospecific Hydroxylation of Camphor Analogs by Cytochrome P450cam , 1995 .
[35] D. Greenblatt,et al. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.
[36] G. Shenfield,et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.
[37] L. Pedersen,et al. Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity (*) , 1996, The Journal of Biological Chemistry.
[38] G H Loew,et al. Construction of a 3D model of cytochrome P450 2B4. , 1997, Protein engineering.
[39] D A Smith,et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[40] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[41] K. Korzekwa,et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.
[42] T. Baillie,et al. Binding of flexible ligands to proteins: Valproic acid and its interaction with cytochrome P450cam , 1993 .
[43] D. Eisenberg,et al. Assessment of protein models with three-dimensional profiles , 1992, Nature.
[44] J. Kerr. Bond Dissociation Energies by Kinetic Methods , 1966 .
[45] S. Wrighton,et al. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.
[46] T. Aoyama,et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.
[47] B C Finzel,et al. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. , 1986, Biochemistry.
[48] K. Griffin,et al. Role of the peroxisome proliferator‐activated receptor in cytochrome P450 4A gene regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] D. Lewis,et al. The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[50] S. Adams,et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin , 1997, Clinical pharmacology and therapeutics.
[51] Roland L. Dunbrack,et al. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. , 1997, Journal of molecular biology.
[52] J. Miners,et al. Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.
[53] T. Richardson,et al. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. , 1998, Biochemistry.
[54] J. Goldstein,et al. Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. , 1996, The Journal of biological chemistry.
[55] P. Ortiz de Montellano,et al. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. , 1998, Biochemistry.
[56] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[57] T. Shimada,et al. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. , 1992, Cancer research.
[58] P. Ortiz de Montellano,et al. The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. , 1988, The Journal of biological chemistry.
[59] D W Nebert,et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.
[60] T. Richardson,et al. Characterization of a cDNA encoding a human kidney, cytochrome P-450 4A fatty acid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli. , 1993, Biochimica et biophysica acta.
[61] T. Richardson,et al. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[62] P. Ortiz de Montellano,et al. Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. , 1984, The Journal of biological chemistry.
[63] O. Gotoh,et al. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.
[64] G. Loew,et al. Refinement of 3D models of horseradish peroxidase isoenzyme C: Predictions of 2D NMR assignments and substrate binding sites , 1996, Proteins.
[65] T. Aoyama,et al. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.
[66] P. Lu,et al. Heteroatom Substitution Shifts Regioselectivity of Lauric Acid Metabolism from ω-Hydroxylation to (ω-1)-Oxidation , 1995 .
[67] C. Breneman,et al. Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .
[68] P. Ortiz de Montellano,et al. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. , 1994, The Journal of pharmacology and experimental therapeutics.
[69] C. Sander,et al. Quality control of protein models : directional atomic contact analysis , 1993 .
[70] T. Edeki,et al. Genetic polymorphism of S-mephenytoin 4'-hydroxylation. , 1996, Psychopharmacology bulletin.
[71] S. Imaoka,et al. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase. , 1993, The Journal of pharmacology and experimental therapeutics.
[72] J. Miners,et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.
[73] B. Masters,et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. , 1993, Circulation research.
[74] S. Imaoka,et al. Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. , 1993, DNA and cell biology.
[75] R. Tukey,et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. , 1996, Biochemical pharmacology.
[76] P. Lu,et al. Fatty acid discrimination and omega-hydroxylation by cytochrome P450 4A1 and a cytochrome P4504A1/NADPH-P450 reductase fusion protein. , 1995, Archives of biochemistry and biophysics.
[77] D. Hi,et al. Genetic polymorphism of S-mephenytoin 4'-hydroxylation. , 1996, Psychopharmacology bulletin.
[78] J. Miners,et al. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.
[79] A. Simpson. The cytochrome P450 4 (CYP4) family. , 1997, General pharmacology.
[80] J. Halpert,et al. Structural determinants of progesterone hydroxylation by cytochrome P450 2B5: the role of nonsubstrate recognition site residues. , 1998, Archives of biochemistry and biophysics.
[81] R. Estabrook,et al. Cytochrome P450 and the arachidonate cascade 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] D. Mansuy,et al. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. , 1996, European journal of biochemistry.
[83] J Deisenhofer,et al. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.
[84] C. Sander,et al. Database algorithm for generating protein backbone and side-chain co-ordinates from a C alpha trace application to model building and detection of co-ordinate errors. , 1991, Journal of molecular biology.
[85] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an NMR study. , 1997, Biochemistry.
[86] M. Wester,et al. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.
[87] J Deisenhofer,et al. Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. , 1994, Journal of molecular biology.
[88] C. Miranda,et al. The regiospecific hydroxylation of lauric acid by rainbow trout (Oncorhynchus mykiss) cytochrome P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[89] E. Gillam,et al. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. , 1997, Chemical research in toxicology.
[90] Roland L. Dunbrack,et al. Conformational analysis of the backbone-dependent rotamer preferences of protein sidechains , 1994, Nature Structural Biology.
[91] R. Levy. Phenytoin: biopharmacology. , 1980, Advances in neurology.
[92] D. Shen,et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[93] T. Poulos,et al. Modeling protein-substrate interactions in the heme domain of cytochrome P450(BM-3). , 1994, Acta crystallographica. Section D, Biological crystallography.
[94] M. Waterman,et al. The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. , 1995, Archives of biochemistry and biophysics.
[95] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[96] M. Komori,et al. Different mechanisms of regioselection of fatty acid hydroxylation by laurate (omega-1)-hydroxylating P450s, P450 2C2 and P450 2E1. , 1994, Journal of Biochemistry (Tokyo).
[97] T. Poulos,et al. Structure of cytochrome P450eryF involved in erythromycin biosynthesis , 1995, Nature Structural Biology.
[98] J. Miners,et al. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. , 1996, Methods in enzymology.
[99] H. Yamazaki,et al. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[100] Manfred J. Sippl,et al. Boltzmann's principle, knowledge-based mean fields and protein folding. An approach to the computational determination of protein structures , 1993, J. Comput. Aided Mol. Des..
[101] A. Fulco,et al. ω-1, ω-2 and ω-3 Hydroxylation of long-chain fatty acids, amides and alcohols by a soluble enzyme system from Bacillus megatyerium , 1975 .
[102] P. D. de Montellano,et al. The Catalytic Site of Cytochrome P4504A11 (CYP4A11) and Its L131F Mutant* , 1998, The Journal of Biological Chemistry.
[103] F. Berthou,et al. Evidence that cytochrome P450 2E1 is involved in the (omega-1)-hydroxylation of lauric acid in rat liver microsomes. , 1994, Biochemical and biophysical research communications.
[104] H. Yamazaki,et al. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[105] B. Rost,et al. Combining evolutionary information and neural networks to predict protein secondary structure , 1994, Proteins.
[106] H. Yamazaki,et al. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.